Palatin Technologies (PTN) Set to Announce Quarterly Earnings on Wednesday

Palatin Technologies (NYSEAMERICAN:PTNGet Free Report) is scheduled to be announcing its earnings results on Wednesday, September 20th.

Palatin Technologies Price Performance

Shares of Palatin Technologies stock opened at $1.86 on Tuesday. The company has a market capitalization of $20.74 million, a price-to-earnings ratio of -0.63 and a beta of 0.95. The firm has a 50-day moving average price of $2.48. The company has a current ratio of 2.05, a quick ratio of 1.99 and a debt-to-equity ratio of 0.01. Palatin Technologies has a one year low of $1.80 and a one year high of $8.60.

Analysts Set New Price Targets

Several research analysts recently commented on the company. cut Palatin Technologies from a “hold” rating to a “sell” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Palatin Technologies in a research note on Monday, August 7th.

Check Out Our Latest Analysis on PTN

Institutional Investors Weigh In On Palatin Technologies

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in shares of Palatin Technologies during the fourth quarter worth approximately $2,167,000. Renaissance Technologies LLC raised its holdings in Palatin Technologies by 388.0% in the 2nd quarter. Renaissance Technologies LLC now owns 226,900 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 180,400 shares in the last quarter. State Street Corp grew its holdings in shares of Palatin Technologies by 8.2% during the 1st quarter. State Street Corp now owns 757,455 shares of the biopharmaceutical company’s stock worth $349,000 after purchasing an additional 57,440 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Palatin Technologies by 0.5% in the first quarter. Vanguard Group Inc. now owns 9,559,564 shares of the biopharmaceutical company’s stock worth $4,398,000 after purchasing an additional 48,812 shares during the period. Finally, Millennium Management LLC acquired a new position in Palatin Technologies in the fourth quarter valued at about $118,000. 7.86% of the stock is currently owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Featured Stories

Earnings History for Palatin Technologies (NYSEAMERICAN:PTN)

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.